Blueprint Medicines’ (BPMC) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has a $97.00 price objective on the biotechnology company’s stock. Other analysts also recently issued reports about the company. Raymond James raised their […]
More Stories
Straumann Holding AG (OTCMKTS:SAUHY) Short Interest Update
Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) was the recipient of a large drop in short interest during the...
AppTech Payments Corp. (NASDAQ:APCX) Short Interest Update
AppTech Payments Corp. (NASDAQ:APCX – Get Free Report) was the target of a large growth in short interest in December....
Deutsche Post AG (OTCMKTS:DHLGY) Sees Significant Growth in Short Interest
Deutsche Post AG (OTCMKTS:DHLGY – Get Free Report) was the target of a significant growth in short interest during the...
Hyundai Motor (OTCMKTS:HYMTF) Short Interest Update
Hyundai Motor (OTCMKTS:HYMTF – Get Free Report) was the target of a significant growth in short interest during the month...
VanEck J.P. Morgan EM Local Currency Bond ETF (NYSEARCA:EMLC) Sets New 12-Month Low – Should You Sell?
Shares of VanEck J.P. Morgan EM Local Currency Bond ETF (NYSEARCA:EMLC – Get Free Report) reached a new 52-week low...
Gevo (NASDAQ:GEVO) Shares Gap Up – Time to Buy?
Gevo, Inc. (NASDAQ:GEVO – Get Free Report) gapped up before the market opened on Friday . The stock had previously...